|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bristow RE, Tomacruz RS, Armstrong DK,
Trimble EL and Montz FJ: Survival effect of maximal cytoreductive
surgery for advanced ovarian carcinoma during the platinum era: A
meta-analysis. J Clin Oncol. 20:1248–1259. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bookman MA, Brady MF, McGuire WP, Harper
PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De
Geest K, et al: Evaluation of new platinum-based treatment regimens
in advanced-stage ovarian cancer: A phase III trial of the
gynecologic cancer intergroup. J Clin Oncol. 27:1419–1425. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wilson MK, Pujade-Lauraine E, Aoki D,
Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon
M, et al: Fifth ovarian cancer consensus conference of the
gynecologic cancer Intergroup: Recurrent disease. Ann Oncol.
28:727–732. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Beesley VL, Green AC, Wyld DK, O'Rourke P,
Wockner LF, DeFazio A, Butow PN, Price MA, Horwood KR, Clavarino
AM, et al: Quality of life and treatment response among women with
platinum-resistant versus platinum-sensitive ovarian cancer treated
for progression: A prospective analysis. Gynecol Oncol.
132:130–136. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pujade-Lauraine E, Hilpert F, Weber B,
Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P,
Bamias A, et al: Bevacizumab combined with chemotherapy for
platinum-resistant recurrent ovarian cancer: The AURELIA open-label
randomized phase III trial. J Clin Oncol. 32:1302–1308. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite instability/mismatch
repair-deficient cancer: Results from the phase II KEYNOTE-158
study. J Clin Oncol. 38:1–10. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stockwell BR, Friedmann Angeli JP, Bayir
H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK,
Kagan VE, et al: Ferroptosis: A regulated cell death nexus linking
metabolism, redox biology, and disease. Cell. 171:273–285. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Feng D, Wang Z, Zhao Y, Sun R, Tian
D, Liu D, Zhang F, Ning S, Yao J and Tian X: Ischemia-induced ACSL4
activation contributes to ferroptosis-mediated tissue injury in
intestinal ischemia/reperfusion. Cell Death Differ. 26:2284–2299.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Derry PJ, Hegde ML, Jackson GR, Kayed R,
Tour JM, Tsai AL and Kent TA: Revisiting the intersection of
amyloid, pathologically modified tau and iron in Alzheimer's
disease from a ferroptosis perspective. Prog Neurobiol.
184:1017162020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lang X, Green MD, Wang W, Yu J, Choi JE,
Jiang L, Liao P, Zhou J, Zhang Q, Dow A, et al: Radiotherapy and
immunotherapy promote tumoral lipid oxidation and ferroptosis via
synergistic repression of SLC7A11. Cancer Discov. 9:1673–1685.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C,
Dai X, Li Z and Wu G: Ferroptosis: A novel anti-tumor action for
cisplatin. Cancer Res Treat. 50:445–460. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xie Y, Hou W, Song X, Yu Y, Huang J, Sun
X, Kang R and Tang D: Ferroptosis: Process and function. Cell Death
Differ. 23:369–379. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang WS, SriRamaratnam R, Welsch ME,
Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji
AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by
GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xie Z, Hou H, Luo D, An R, Zhao Y and Qiu
C: ROS-dependent lipid peroxidation and reliant antioxidant
ferroptosis-suppressor-protein 1 in rheumatoid arthritis: A covert
clue for potential therapy. Inflammation. 44:35–47. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bersuker K, Hendricks JM, Li Z, Magtanong
L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, et al:
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit
ferroptosis. Nature. 575:688–692. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Doll S, Freitas FP, Shah R, Aldrovandi M,
da Silva MC, Ingold I, Goya Grocin A, Xavier da Silva TN, Panzilius
E, Scheel CH, et al: FSP1 is a glutathione-independent ferroptosis
suppressor. Nature. 575:693–698. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ikeda Y, Hamano H, Horinouchi Y, Miyamoto
L, Hirayama T, Nagasawa H, Tamaki T and Tsuchiya K: Role of
ferroptosis in cisplatin-induced acute nephrotoxicity in mice. J
Trace Elem Med Biol. 67:1267982021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sato M, Kusumi R, Hamashima S, Kobayashi
S, Sasaki S, Komiyama Y, Izumikawa T, Conrad M, Bannai S and Sato
H: The ferroptosis inducer erastin irreversibly inhibits system
xc- and synergizes with cisplatin to increase
cisplatin's cytotoxicity in cancer cells. Sci Rep. 8:9682018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu X, Shen S, Qin J, Fei W, Fan F, Gu J,
Shen T, Zhang T and Cheng X: High co-expression of SLC7A11 and GPX4
as a predictor of platinum resistance and poor prognosis in
patients with epithelial ovarian cancer. BJOG. 129 (Suppl
2):S40–S49. 2022. View Article : Google Scholar
|
|
22
|
Grinberg AV, Hannemann F, Schiffler B,
Müller J, Heinemann U and Bernhardt R: Adrenodoxin: Structure,
stability, and electron transfer properties. Proteins. 40:590–612.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sheftel AD, Stehling O, Pierik AJ,
Elsässer HP, Mühlenhoff U, Webert H, Hobler A, Hannemann F,
Bernhardt R and Lill R: Humans possess two mitochondrial
ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis,
heme, and Fe/S cluster biosynthesis. Proc Natl Acad Sci USA.
107:11775–11780. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shi Y, Ghosh M, Kovtunovych G, Crooks DR
and Rouault TA: Both human ferredoxins 1 and 2 and ferredoxin
reductase are important for iron-sulfur cluster biogenesis. Biochim
Biophys Acta. 1823:484–492. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang C, Zeng Y, Guo X, Shen H, Zhang J,
Wang K, Ji M and Huang S: Pan-cancer analyses confirmed the
cuproptosis-related gene FDX1 as an immunotherapy predictor and
prognostic biomarker. Front Genet. 13:9237372022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Z, Ma Y, Guo X, Du Y, Zhu Q, Wang X
and Duan C: FDX1 can impact the prognosis and mediate the
metabolism of lung adenocarcinoma. Front Pharmacol. 12:7491342021.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Okamoto D, Yamauchi N, Takiguchi G,
Nishita M, Kakeji Y, Minami Y and Kamizaki K: Autonomous and
intercellular chemokine signaling elicited from mesenchymal stem
cells regulates migration of undifferentiated gastric cancer cells.
Genes Cells. 27:368–375. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Avincsal MO, Kamizaki K, Jimbo N,
Shinomiya H, Nibu KI, Nishita M and Minami Y: Oncogenic E6 and/or
E7 proteins drive proliferation and invasion of human papilloma
virus-positive head and neck squamous cell cancer through
upregulation of Ror2 expression. Oncol Rep. 46:1482021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Behrens BC, Hamilton TC, Masuda H,
Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young
RC and Ozols RF: Characterization of a
cis-diamminedichloroplatinum(II)-resistant human ovarian cancer
cell line and its use in evaluation of platinum analogues. Cancer
Res. 47:414–418. 1987.PubMed/NCBI
|
|
30
|
Chen L, Min J and Wang F: Copper
homeostasis and cuproptosis in health and disease. Signal Transduct
Target Ther. 7:3782022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tsvetkov P, Coy S, Petrova B, Dreishpoon
M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R,
Spangler RD, et al: Copper induces cell death by targeting
lipoylated TCA cycle proteins. Science. 375:1254–1261. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao M, Yi J, Zhu J, Minikes AM, Monian P,
Thompson CB and Jiang X: Role of mitochondria in ferroptosis. Mol
Cell. 73:354–363.e3. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang D and Lippard SJ: Cellular processing
of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ciriello G, Miller ML, Aksoy BA,
Senbabaoglu Y, Schultz N and Sander C: Emerging landscape of
oncogenic signatures across human cancers. Nat Genet. 45:1127–1133.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cancer Genome Atlas Research Network, .
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hollis RL, Thomson JP, Stanley B,
Churchman M, Meynert AM, Rye T, Bartos C, Iida Y, Croy I, Mackean
M, et al: Molecular stratification of endometrioid ovarian
carcinoma predicts clinical outcome. Nat Commun. 11:49952020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Noriega-Rivera R, Rivera-Serrano M,
Rabelo-Fernandez RJ, Pérez-Santiago J, Valiyeva F and Vivas-Mejía
PE: Upregulation of the long noncoding RNA CASC10 promotes
cisplatin resistance in high-grade serous ovarian cancer. Int J Mol
Sci. 23:77372022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Viscarra T, Buchegger K, Jofre I, Riquelme
I, Zanella L, Abanto M, Parker AC, Piccolo SR, Roa JC, Ili C and
Brebi P: Functional and transcriptomic characterization of
carboplatin-resistant A2780 ovarian cancer cell line. Biol Res.
52:132019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sun J, Cai X, Yung MM, Zhou W, Li J, Zhang
Y, Li Z, Liu SS, Cheung ANY, Ngan HYS, et al: miR-137 mediates the
functional link between c-Myc and EZH2 that regulates cisplatin
resistance in ovarian cancer. Oncogene. 38:564–580. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Meng Y, Chen CW, Yung MMH, Sun W, Sun J,
Li Z, Li J, Li Z, Zhou W, Liu SS, et al: DUOXA1-mediated ROS
production promotes cisplatin resistance by activating ATR-Chk1
pathway in ovarian cancer. Cancer Lett. 428:104–116. 2018.
View Article : Google Scholar : PubMed/NCBI
|
